35 results on '"García Sepulcre M"'
Search Results
2. P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
- Author
-
Gargallo-Puyuelo, C, primary, Ricard, E, additional, Iborra, M, additional, Iglesias-Flores, E, additional, Vera Mendoza, I, additional, De Francisco García, R, additional, Calafat Sard, M, additional, Minguez, M, additional, Lopez- San Roman, A, additional, Taxonera, C, additional, Guardiola, J, additional, Barrio, J, additional, Laredo, V, additional, De Castro, L, additional, Gisbert, J, additional, García-Lopez, S, additional, García Planella, E, additional, Martín Arranz, D, additional, Calvet, X, additional, Merino, O, additional, Sierra, M, additional, Marquez, L, additional, Madero, L, additional, Varela, P, additional, Carpio, D, additional, Esteve, M, additional, Rivero, M, additional, Ramos, L, additional, Sicilia, B, additional, Lorente POyatos, R, additional, Marin, I, additional, Monfort, D, additional, Navarro, M, additional, VEga, P, additional, Hinojosa, J, additional, Tardillo, C, additional, García Sepulcre, M F, additional, Barreiro, M, additional, Domenech, E, additional, and Gomollón, F, additional
- Published
- 2023
- Full Text
- View/download PDF
3. P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry
- Author
-
Calafat Sard, M, primary, Pascual, I, additional, Nos, P, additional, Barrio, J, additional, Gutiérrez, A, additional, Martín-Arranz, M D, additional, Ricart, E, additional, Gomollón, F, additional, Sierra Ausín, M, additional, Huguet, J M, additional, Guardiola, J, additional, Vera, I, additional, Varela, P, additional, Iglesias, E, additional, Garcia-Planella, E, additional, de Castro, L, additional, García Sepulcre, M F, additional, Sicilia, B, additional, Fernández-Salazar, L, additional, Calvet, X, additional, Muñoz, F, additional, García-López, S, additional, Bermejo, F, additional, Ramos, L, additional, Martínez Montiel, P, additional, Lorente, R, additional, Cabriada, J L, additional, Piqueras, M, additional, Marín-Jiménez, I, additional, Esteve, M, additional, Mesonero, F, additional, Sesé, E, additional, Gisbert, J P, additional, Márquez, L, additional, Busquets, D, additional, Pajares, R, additional, Cañete, F, additional, Mañosa, M, additional, and Domènech, E, additional
- Published
- 2023
- Full Text
- View/download PDF
4. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
- Author
-
Calafat, M, Mañosa, M, Cañete, F, Panés, J, García Sánchez, V, Calvo, M, Rodríguez-Moranta, F, Taxonera, C, Nos, P, López Sanromán, A, Martín Arranz, M D, Mínguez, M, Gisbert, J P, García-López, S, de Francisco, R, Gomollón, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martínez-Cadilla, J, Argüelles, F, Arias García, L, Cimavilla, M, Zabana, Y, Márquez, L, Gutiérrez, A, Alcaín, G, Martínez Montiel, P, Lázaro, J, Busquets, D, García Sepulcre, M F, Verdejo, C, Bermejo, F, Mora, M, Monfort, D, Romero, P, Velayos, B, Rodríguez, C, Rodríguez, A, Merino, O, Rodríguez-Pescador, A, Bujanda, L, Ber, Y, Vela, M, Roncero, O, Huguet, J M, García-Bosch, O, Barreiro-de-Acosta, M, Madrigal, R E, Ramos, L, Van Domselaar, M, Almela, P, Llaó, J, Lucendo, A J, Muñoz Vilafranca, C, Abad, À, Charro, M, Legido, J, Riera, J, Khorrami, S, Sesé, E, Trapero, A M, and Domènech, E
- Published
- 2018
- Full Text
- View/download PDF
5. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
- Author
-
Zabana Abdo, Y, primary, Marín-Jiménez, I, additional, Rodríguez-Lago, I, additional, Ramírez Esteso, F, additional, Meijilde, S, additional, Ramos, L, additional, Gomollón, F, additional, Muñoz, F, additional, Suris, G, additional, Ortiz de Zárate, J, additional, Huguet, J M, additional, Llaó, J, additional, García-Sepulcre, M, additional, Sierra, M, additional, Durà, M, additional, Estrecha, S, additional, Fuentes Coronel, A, additional, Hinojosa, E, additional, Olivan, L, additional, Iglesias, E, additional, Gutiérrez, A, additional, Varela, P, additional, Rull, N, additional, Gilabert, P, additional, Hernández-Camba, A, additional, Brotons, A, additional, Ginard, D, additional, Sesé, E, additional, Carpio, D, additional, Aceituno, M, additional, Cabriada, J L, additional, González-Lama, Y, additional, Jiménez, L, additional, Chaparro, M, additional, López-San Román, A, additional, Alba, C, additional, Plaza-Santos, R, additional, Piqueras, M, additional, Domènech, E, additional, and Esteve, M, additional
- Published
- 2021
- Full Text
- View/download PDF
6. P357 Long-term outcomes of biologic therapy in Crohn’s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU
- Author
-
Rodríguez-Lago, I, primary, Fernández-Clotet, A, additional, Mesonero, F, additional, García-Alonso, F J, additional, Casanova, M J, additional, Fernández-de la Varga, M, additional, Cañete, F, additional, de Castro, L, additional, Gutiérrez, A, additional, Sicilia, B, additional, Cano, V, additional, Merino, O, additional, Riestra, S, additional, González-Partida, I, additional, Surís, G, additional, Torrealba, L, additional, Ferreiro-Iglesias, R, additional, Castro, B, additional, Márquez, L, additional, Sobrino, A, additional, Elorza, A, additional, Calvet, X, additional, Varela, P, additional, Betoré, E, additional, Bujanda, L, additional, Lario, L, additional, Manceñido, N, additional, García-Sepulcre, M, additional, Iglesias, E, additional, Rodríguez, C, additional, Piqueras, M, additional, Ferrer Rosique, J Á, additional, Lucendo, A, additional, Benítez, O, additional, García, M, additional, Olivares, D, additional, González-Muñoza, C, additional, Cabriada, J L, additional, Domènech, E, additional, and Barreiro-de Acosta, M, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
- Author
-
Nunes, T., Etchevers, M. J., Domènech, E., García-Sánchez, V., Ber, Y., Peñalva, M., Merino, O., Nos, P., Garcia-Planella, E., Casbas, A. G., Esteve, M., Samsó, Taxonera C., Huguet, Montoro M., Gisbert, J. P., Arranz, M. D.Martín, García-Sepulcre, M. F., de Acosta, Barreiro- M., Beltrán, B., Suárez, Alcaide N., Gismera, Saro C., Cabriada, J. L., Cañas-Ventura, A., Gomollón, F., and Panés, J.
- Published
- 2013
- Full Text
- View/download PDF
8. P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
- Author
-
Chaparro, M, primary, Sulleiro, S, additional, Bastón-Rey, I, additional, Rodríguez, C, additional, García-Tercero, I, additional, Ramírez, P, additional, García-López, S, additional, Rojas-Feria, M, additional, Gutiérrez, A, additional, Huguet Malavés, J M, additional, García-Sepulcre, M F, additional, Sicilia, B, additional, Bermejo, F, additional, Rodríguez-Moranta, F, additional, Argüelles, F, additional, Marín, I, additional, Leo, E, additional, Arroyo, M, additional, García, M J, additional, Vázquez, J M, additional, Ginard, D, additional, Martínez Cadilla, J, additional, Rubín de Célix, C, additional, García-Herola, A, additional, Hernández-Camba, A, additional, Martín-Arranz, M D, additional, Riestra, S, additional, Varela, P, additional, Velayos, B, additional, Busquets, D, additional, Dueñas, C, additional, Fernández-Salgado, E, additional, Martínez-Montiel, P, additional, Diz-Lois, M T, additional, González-Lama, Y, additional, Muñagorri, A, additional, Navarro-Llavat, M, additional, Guisado, C, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional
- Published
- 2020
- Full Text
- View/download PDF
9. P800 Factors related to non-adherence behaviours of patients with inflammatory bowel disease
- Author
-
Marín-Jiménez, I, primary, Casellas, F, additional, García-Sepulcre, M F, additional, Navarro-Correal, E, additional, Juliá, B, additional, Soto, N, additional, and Cea-Calvo, L, additional
- Published
- 2019
- Full Text
- View/download PDF
10. P505 Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry
- Author
-
Iborra, M, primary, Beltrán, B, additional, Fernández, A, additional, Gutiérrez, A, additional, Antolín, B, additional, Huguet, J M, additional, de Francisco, R, additional, Merino, O, additional, Carpio, D, additional, García López, S, additional, Mesonero, F, additional, Mínguez, M, additional, Ferreiro, R, additional, Carbajo, A Y, additional, Rivero, M, additional, Chaparro, M, additional, Piñero-Pérez, M C, additional, Monfort i Miquel, D, additional, Bujanda, L, additional, García-Sepulcre, M F, additional, Martín-Cardona, A, additional, Cañete, F, additional, Taxonera, C, additional, Sierra-Ausin, M, additional, Ferrer-Rosique, J Á, additional, Martín-Arranz, M D, additional, González-Muñosa, C, additional, Manceñido-Marcos, N, additional, Rodríguez-Lago, I, additional, Iglesias-Flores, E, additional, Forés-Bosch, A, additional, Navarro-Llavat, M, additional, Calafat, M, additional, Madrigal-Domínguez, R E, additional, Ramos, L, additional, Arroyo, M, additional, Busquets, D, additional, Lorente, R, additional, Saiz-Arnau, E, additional, Hernández-Camba, A, additional, Jair-Morales, V, additional, Paredes, C, additional, Van Domselaar, M, additional, Hervás, D, additional, Cañada-Martínez, A, additional, and Nos, P, additional
- Published
- 2019
- Full Text
- View/download PDF
11. P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
- Author
-
Casanova, M J, primary, Chaparro, M, additional, Mínguez, M, additional, Ricart, E, additional, Taxonera, C, additional, García-López, S, additional, Guardiola, J, additional, López-San Román, A, additional, Iglesias, E, additional, Beltrán, B, additional, Sicilia, B, additional, Vera, M I, additional, Hinojosa, J, additional, Riestra, S, additional, Domènech, E, additional, Calvet, X, additional, Pérez-Calle, J L, additional, Martín-Arranz, M D, additional, Aldeguer, X, additional, Rivero, M, additional, Monfort, D, additional, Barrio, J, additional, Esteve, M, additional, Márquez, L, additional, Lorente, R, additional, García-Planella, E, additional, de Castro, L, additional, Bermejo, F, additional, Merino, O, additional, Rodríguez-Pérez, A, additional, Martínez-Montiel, P, additional, Van Domselaar, M, additional, Alcaín, G, additional, Domínguez-Cajal, M, additional, Muñoz, C, additional, Gomollón, F, additional, Fernández-Salazar, L, additional, García-Sepulcre, M F, additional, Rodríguez-Lago, I, additional, Gutiérrez, A, additional, Argüelles-Arias, F, additional, Rodriguez, C, additional, Rodríguez, G E, additional, Bujanda, L, additional, Llaó, J, additional, Varela, P, additional, Ramos, L, additional, Huguet, J M, additional, Almela, P, additional, Romero, P, additional, Navarro-Llavat, M, additional, Abad, Á, additional, Ramírez-de la Piscina, P, additional, Lucendo, A J, additional, Sesé, E, additional, Madrigal, R E, additional, Charro, M, additional, García-Herola, A, additional, Pajares, R, additional, Khorrami, S, additional, and Gisbert, J P, additional
- Published
- 2019
- Full Text
- View/download PDF
12. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU
- Author
-
Chaparro, M, primary, Garre, A, additional, Ricart, E, additional, García-Sánchez, V, additional, Taxonera, C, additional, Mañosa, M, additional, Vera Mendoza, I, additional, Mínguez, M, additional, Argüelles, F, additional, De Castro Parga, L, additional, Arroyo, M, additional, López-San Román, A, additional, Rivero Tirado, M, additional, Guardiola, J, additional, Martín Arranz, M D, additional, Beltrán, B, additional, Barrio, J, additional, Riestra, S, additional, García-Planella, E, additional, Calvet, X, additional, Alcaín, G, additional, Sicilia, B, additional, García, S, additional, Esteve, M, additional, Márquez, L, additional, Fernández Salazar, L, additional, Gutiérrez Casbas, A, additional, Piqueras, M, additional, Guerra, I, additional, Pérez Calle, J L, additional, Hinojosa, J, additional, Rodríguez, A, additional, Aldeguer, X, additional, García-Sepulcre, M, additional, Bujanda, L, additional, Martínez Montiel, P, additional, Llorente Poyatos, R, additional, Rodríguez Gutiérrez, C, additional, Merino, O, additional, Cabriada, J L, additional, Roncero, O, additional, Romero Cara, P, additional, Navarro-Llavat, M, additional, Ber, Y, additional, Madrigal, R, additional, Van Domselaar, M, additional, Barreiro-de Acosta, M, additional, Llao, J, additional, Ramos, L, additional, Riera, J, additional, Lucendo Villarín, A J, additional, Rodríguez González, E, additional, Huguet Malavés, J M, additional, Muñoz Villafranca, C, additional, Almela, P, additional, Charro, M, additional, Ramírez de la Piscina, P, additional, Sese, E, additional, Abad Lacruz, Á, additional, Khorrami, S, additional, Morales Alvarado, V J, additional, Legido Gil, J, additional, Trapero Martínez, A M, additional, Pajares, R, additional, Acevedo, J, additional, García Herola, A, additional, Hernández Villalba, L, additional, Muñoz, E, additional, Novella Durán, M T, additional, Menacho, M, additional, Navas López, V M, additional, Retamero, M D, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2018
- Full Text
- View/download PDF
13. P666 Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
- Author
-
Chaparro, M, primary, Garre, A, additional, Alfaro, I, additional, Iborra, M, additional, Mesonero, P, additional, Vera Mendoza, I, additional, Rodríguez, A, additional, Miquel-Cusachs, J, additional, Riestra, S, additional, Navarro, P, additional, De Castro Parga, L, additional, González-Muñoza, C, additional, Rivero Tirado, M, additional, Mañosa, M, additional, Fernández Salazar, L, additional, García-Sepulcre, M, additional, Guardiola, J, additional, Cabriada, J, additional, Gutiérrez Casbas, A, additional, Sicilia, B, additional, Pérez Calle, J L, additional, Piqueras, M, additional, Guerra, I, additional, Roncero, O, additional, Navarro-Llavat, M, additional, Sainz, E, additional, Barrio, J, additional, Calvet, X, additional, García, A, additional, Llorente Barrio, M, additional, Lorente, R, additional, Almela, P, additional, Madrigal, R, additional, Lucendo Villarín, A J, additional, Pajares, R, additional, Van Domselaar, M, additional, Legido Gil, J, additional, and Gisbert, J P, additional
- Published
- 2018
- Full Text
- View/download PDF
14. P275 Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Spanish nationwide study based on the ENEIDA registry
- Author
-
Guerra, I, primary, Bujanda, L, additional, Castro, J, additional, Merino, O, additional, Tosca, J, additional, Camps, B, additional, Gutiérrez, A, additional, Gordillo, J, additional, de Castro, L, additional, Iborra, M, additional, Carbajo, A Y, additional, Taxonera, C, additional, Rodriguez - Lago, I, additional, Mesonero, F, additional, de Francisco, R, additional, Gómez-Gómez, G J, additional, Chaparro, M, additional, Tardillo, C A, additional, Rivero, M, additional, Algaba, A, additional, Martín-Arranz, E, additional, Cañete, F, additional, Vicente, R, additional, Sicilia, B, additional, Antolín, B, additional, Prieto, V, additional, Márquez, L, additional, Benítez, J M, additional, Camo, P, additional, Piqueras, M, additional, Gargallo, C J, additional, Hinojosa, E, additional, Huguet, J M, additional, Pérez Calle, J L, additional, Van Domselaar, M, additional, Rodriguez, C, additional, Calvet, X, additional, Muñoz, M C, additional, García-Sepulcre, M F, additional, Bermejo, F, additional, Bañales, J M, additional, and Gisbert, J P, additional
- Published
- 2018
- Full Text
- View/download PDF
15. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989–2013): A Nationwide Multicenter Study
- Author
-
Ordás, I, primary, Domènech, E, additional, Mañosa, M, additional, García-Sánchez, V, additional, Iglesias-Flores, E, additional, Peñalva, M, additional, Cañas-Ventura, A, additional, Merino, O, additional, Fernández-Bañares, F, additional, Gomollón, F, additional, Vera, M, additional, Gutiérrez, A, additional, Garcia-Planella, E, additional, Chaparro, M, additional, Aguas, M, additional, Gento, E, additional, Muñoz, F, additional, Aguirresarobe, M, additional, Muñoz, C, additional, Fernández, L, additional, Calvet, X, additional, Jiménez, C E, additional, Montoro, M A, additional, Mir, A, additional, De Castro, M L, additional, García-Sepulcre, M F, additional, Bermejo, F, additional, Panés, J, additional, and Esteve, M, additional
- Published
- 2017
- Full Text
- View/download PDF
16. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry
- Author
-
Chaparro, María, primary, Ramas, M, additional, Benítez, J M, additional, López-García, A, additional, Juan, A, additional, Guardiola, J, additional, Mínguez, M, additional, Calvet, X, additional, Márquez, L, additional, Salazar, L I Fernández, additional, Bujanda, L, additional, García, C, additional, Zabana, Y, additional, Lorente, R, additional, Barrio, J, additional, Hinojosa, E, additional, Iborra, M, additional, Cajal, Domínguez M, additional, Van Domselaar, M, additional, García-Sepulcre, M F, additional, Gomollón, F, additional, Piqueras, M, additional, Alcaín, G, additional, García-Sánchez, V, additional, Panés, J, additional, Domènech, E, additional, García-Esquinas, E, additional, Rodríguez-Artalejo, F, additional, and Gisbert, J P, additional
- Published
- 2017
- Full Text
- View/download PDF
17. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
- Author
-
Casanova, M J, primary, Chaparro, M, additional, García-Sánchez, V, additional, Nantes, O, additional, Leo, E, additional, Rojas-Feria, M, additional, Jauregui-Amezaga, A, additional, García-López, S, additional, Huguet, J M, additional, Arguelles-Arias, F, additional, Aicart, M, additional, Marín-Jiménez, I, additional, Gómez-García, M, additional, Muñoz, F, additional, Esteve, M, additional, Bujanda, L, additional, Cortés, X, additional, Tosca, J, additional, Pineda, J R, additional, Mañosa, M, additional, Llaó, J, additional, Guardiola, J, additional, Pérez-Martínez, I, additional, Muñoz, C, additional, González-Lama, Y, additional, Hinojosa, J, additional, Vázquez, J M, additional, Martinez-Montiel, M P, additional, Rodríguez, G E, additional, Pajares, R, additional, García-Sepulcre, M F, additional, Hernández-Martínez, A, additional, Pérez-Calle, J L, additional, Beltrán, B, additional, Busquets, D, additional, Ramos, L, additional, Bermejo, F, additional, Barrio, J, additional, Barreiro-de Acosta, M, additional, Roncedo, O, additional, Calvet, X, additional, Hervías, D, additional, Gomollón, F, additional, Domínguez-Antonaya, M, additional, Alcaín, G, additional, Sicilia, B, additional, Dueñas, C, additional, Gutiérrez, A, additional, Lorente-Poyatos, R, additional, Domínguez, M, additional, Khorrami, S, additional, Taxonera, C, additional, Rodríguez-Pérez, A, additional, Ponferrada, A, additional, Van Domselaar, M, additional, Arias-Rivera, M L, additional, Merino, O, additional, Castro, E, additional, Marrero, J M, additional, Martín-Arranz, M, additional, Botella, B, additional, Fernández-Salazar, L, additional, Monfort, D, additional, Opio, V, additional, García-Herola, A, additional, Menacho, M, additional, la Piscina, Ramírez-de P, additional, Ceballos, D, additional, Almela, P, additional, Navarro-Llavat, M, additional, Robles-Alonso, V, additional, Vega-López, A B, additional, Moraleja, I, additional, Novella, M T, additional, Castaño-Milla, C, additional, Sánchez-Torres, A, additional, Benítez, J M, additional, Rodríguez, C, additional, Castro, L, additional, Garrido, E, additional, Domènech, E, additional, García-Planella, E, additional, and Gisbert, J P, additional
- Published
- 2017
- Full Text
- View/download PDF
18. Hepatotoxicidad tras tratamiento con ciclofosfamida en un paciente con vasculitis MPO-ANCA
- Author
-
Martínez-Gabarrón, M., Enríquez, R., Sirvent, A.E., García-Sepulcre, M., Millán, I., and Amorós, F.
- Published
- 2011
19. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy
- Author
-
Ramos, J. M., García-Sepulcre, M. F., Masiá, M., Brotons, A., Grau, M. C., and Gutiérrez, F.
- Published
- 2010
20. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy
- Author
-
Ramos, J. M., primary, García-Sepulcre, M. F., additional, Masiá, M., additional, Brotons, A., additional, Grau, M. C., additional, and Gutiérrez, F., additional
- Published
- 2010
- Full Text
- View/download PDF
21. W1193 Safety of Thiopurine Therapy in Inflammatory Bowel Disease (IBD): Long-Term Follow-up Study of 3,900 Patients
- Author
-
Chaparro, Maria, primary, Ordas, Ingrid, additional, Cabre, Eduardo, additional, Garcia, Valle, additional, Bastida, Guillermo, additional, Penalva, Mireia, additional, Gomollon, Fernando, additional, Garcia-Planella, Esther, additional, Merino, Olga, additional, Gutiérrez, Ana, additional, Esteve, Maria, additional, Andreu, Montserrat, additional, García-Sepulcre, M., additional, Hinojosa, Joaquín, additional, Vera, Isabel, additional, Muñoz, Fernando, additional, Mendoza, Juan L., additional, Cabriada, Jose Luis, additional, Montoro, Miguel A., additional, Barreiro, Manuel, additional, Ceña, Gloria, additional, Saro, Cristina, additional, Mante, Xavier Aldeguer, additional, Barrio, Jesus, additional, and Gisbert, Javier P., additional
- Published
- 2010
- Full Text
- View/download PDF
22. Hepatotoxicity following cyclophosphamide treatment in a patient with MPO-ANCA vasculitis.
- Author
-
Martínez-Gabarrón, M., Enríquez, R., Sirvent, A. E., García-Sepulcre, M., Millán, I., and Amorós, F.
- Abstract
A letter to the editor is presented which discusses a case of a 57-year-old patient with an increase in hepatic and pancreatic enzymes and abdominal pain after cyclophosphamide administration.
- Published
- 2011
- Full Text
- View/download PDF
23. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
- Author
-
Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, Arroyo M, Bosca-Watts MM, Diz-Lois Palomares MT, Menchén L, Martínez Cadilla J, Leo-Carnerero E, Muñoz Villafranca C, Sierra-Ausín M, González-Lama Y, Riestra S, Sendra Rumbeu P, Cabello Tapia MJ, García de la Filia I, Vicente R, Ceballos D, Pajares Villarroya R, Ramírez de la Piscina P, Martín-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Pérez TJ, San Miguel Amelivia E, Calvet X, Huguet JM, Keco-Huerga A, Lorente Poyatos RH, Muñoz JF, Ponferrada-Díaz Á, Sicilia B, Delgado-Guillena P, Gómez Delgado E, Rancel-Medina FJ, Alonso-Galán H, Herreros B, Rivero M, Varela P, Bermejo F, García Sepulcre M, Gimeno-Pitarch L, Kolle-Casso L, Márquez-Mosquera L, Martínez Tirado P, Ramírez C, Sesé Abizanda E, Dueñas Sadornil C, Fernández Rosáenz H, Gutiérrez Casbas A, Madrigal Domínguez RE, Nantes Castillejo Ó, Ber Nieto Y, Botella Mateu B, Frago Larramona S, López Serrano P, Rubio Mateos JM, Torrá Alsina S, Iyo E, Fernández Forcelledo JL, Hernández L, Rodríguez-Grau MC, Monfort Miquel D, Van Domselaar M, López Ramos C, Ruiz Barcia MJ, and Gisbert JP
- Abstract
Background: Ustekinumab is approved for ulcerative colitis (UC)., Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice., Methods: Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission., Results: We included 620 patients; 155 (25%) discontinued ustekinumab during follow-up (median 12 months). Rate of discontinuation was 20% per patient-year of follow-up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1-2.1), steroids at baseline (HR 1.5; 95% CI 1.06-2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09-2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid-free clinical remission. Moderate-severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2-0.5), male sex (OR 0.5; 95% CI 0.4-0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6-0.8) were associated with lower likelihood of steroid-free clinical remission at week 16. One hundred and seventy-six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune-mediated diseases., Conclusions: Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies., (© 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
24. Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.
- Author
-
González-Muñoza C, Calafat M, Gisbert JP, Iglesias E, Mínguez M, Sicilia B, Aceituno M, Gomollón F, Calvet X, Ricart E, De Castro L, Rivero M, Mesonero F, Márquez L, Nos P, Rodríguez-Pescador A, Guardiola J, García-Sepulcre M, García-López S, Lorente-Poyatos RH, Alba C, Sánchez-Ocaña R, Vera I, Madero L, Riestra S, Navarro-Llavat M, Pérez-Calle JL, Camps B, Van Domselaar M, Lucendo AJ, Martín-Arranz MD, Montoro-Huguet MA, Sierra-Ausín M, Llaó J, Carpio D, Varela P, Merino O, Fernández-Salazar LI, Piqueras M, Sesé E, Busquets D, Tardillo C, Maroto N, Riera J, Martínez-Flores C, Muñoz F, Gordillo-Ábalos J, Bertoletti F, Garcia-Planella E, and Domènech E
- Abstract
Background and Aims: Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the use of medical and surgical treatments in the biological era., Methods: Patients included in the prospectively maintained ENEIDA database and diagnosed with IBD after 2005 were included. Familial forms were defined as those cases with at least one first-degree relative diagnosed with IBD. Disease phenotype, the use of biological agents, or surgical treatments were the main outcomes., Results: A total of 5263 patients [2627 Crohn's disease (CD); 2636 ulcerative colitis (UC)] were included, with a median follow-up of 31 months. Of these, 507 (10%) corresponded to familial forms. No clinical differences were observed between familial and sporadic IBD forms except a lower age at IBD diagnosis and a higher rate of males in familial forms of UC. In CD, the proportions of patients treated with thiopurines (54.4% vs 46.7%; P = .015) and survival time free of thiopurines (P = .009) were lower in familial forms. No differences were found regarding the use of biological agents. Concerning surgery, a higher rate of intestinal resections was observed in sporadic CD (14.8% vs 9.9%, P = .027). No differences were observed in UC., Conclusions: In the era of biological therapies, familial and sporadic forms of IBD show similar phenotypes and are managed medically in a similar way; whether these is due to lack of phenotypical differences or an effect of biological therapies is uncertain. What is already known on this topic: IBD's etiopathogenesis points to an interaction between environmental and genetic factors, being familial history a controversial prognostic factor. Biological agents use and need for surgery regarding familial or sporadic forms of IBDs present conflicting results. What this study adds: Familial and sporadic forms of IBD have similar phenotypes and are managed medically and surgically in a similar way. How this study might affect research, practice or policy: Familial aggregation should not be considered a factor associated with more aggressive disease., (© The Author(s) 2024. Published by Oxford University Press on behalf of Fellowship of Postgraduate Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
25. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.
- Author
-
Chaparro M, Acosta D, Rodríguez C, Mesonero F, Vicuña M, Barreiro-de Acosta M, Fernández-Clotet A, Hernández Martínez Á, Arroyo M, Vera I, Ruiz-Cerulla A, Sicilia B, Cabello Tapia MJ, Muñoz Villafranca C, Castro-Poceiro J, Martínez Cadilla J, Sierra-Ausín M, Vázquez Morón JM, Vicente Lidón R, Bermejo F, Royo V, Calafat M, González-Muñoza C, Leo Carnerero E, Manceñido Marcos N, Torrealba L, Alonso-Galán H, Benítez JM, Ber Nieto Y, Diz-Lois Palomares MT, García MJ, Muñoz JF, Armesto González EM, Calvet X, Hernández-Camba A, Madrigal Domínguez RE, Menchén L, Pérez Calle JL, Piqueras M, Dueñas Sadornil C, Botella B, Martínez-Pérez TJ, Ramos L, Rodríguez-Grau MC, San Miguel E, Fernández Forcelledo JL, Fradejas Salazar PM, García-Sepulcre M, Gutiérrez A, Llaó J, Sesé Abizanda E, Boscá-Watts M, Iyo E, Keco-Huerga A, Martínez Bonil C, Peña González E, Pérez-Galindo P, Varela P, and Gisbert JP
- Subjects
- Humans, Treatment Outcome, Remission Induction, Retrospective Studies, Colitis, Ulcerative drug therapy
- Abstract
Introduction: The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice., Methods: This is a retrospective multicenter study including patients with UC who had received the first tofacitinib dose at least 8 weeks before the inclusion. Clinical effectiveness was based on partial Mayo score., Results: A total of 408 patients were included. Of them, 184 (45%) withdrew tofacitinib during follow-up (mean = 18 months). The probability of maintaining tofacitinib was 67% at 6 m, 58% at 12 m, and 49% at 24 m. The main reason for tofacitinib withdrawal was primary nonresponse (44%). Older age at the start of tofacitinib and a higher severity of clinical activity were associated with tofacitinib withdrawal. The proportion of patients in remission was 38% at week 4, 45% at week 8, and 47% at week 16. Having moderate-to-severe vs mild disease activity at baseline and older age at tofacitinib start were associated with a lower and higher likelihood of remission at week 8, respectively. Of 171 patients in remission at week 8, 83 (49%) relapsed. The probability of maintaining response was 66% at 6 m and 54% at 12 m. There were 93 adverse events related to tofacitinib treatment (including 2 pulmonary thromboembolisms [in patients with risk factors] and 2 peripheral vascular thrombosis), and 29 led to tofacitinib discontinuation., Discussion: Tofacitinib is effective in both short-term and long-term in patients with UC. The safety profile is similar to that previously reported., (Copyright © 2023 by The American College of Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
26. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU.
- Author
-
Barreiro-de Acosta M, Riestra S, Calafat M, Soto MP, Calvo M, Sánchez Rodríguez E, Caballol B, Vela M, Rivero M, Muñoz F, de Castro L, Calvet X, García-Alonso FJ, Utrilla Fornals A, Ferreiro-Iglesias R, González-Muñoza C, Chaparro M, Bujanda L, Sicilia B, Alfambra E, Rodríguez A, Pérez Fernández R, Rodríguez C, Almela P, Argüelles F, Busquets D, Tamarit-Sebastián S, Reygosa Castro C, Jiménez L, Marín-Jiménez I, Alcaide N, Fernández-Salgado E, Iglesias Á, Ponferrada Á, Pajares R, Roncero Ó, Morales-Alvarado VJ, Ispízua-Madariaga N, Sáinz E, Merino O, Márquez-Mosquera L, García-Sepulcre M, Elorza A, Estrecha S, Surís G, Van Domselaar M, Brotons A, de Francisco R, Cañete F, Iglesias E, Vera MI, Mesonero F, Lorente R, Zabana Y, Cabriada JL, Domènech E, and Rodríguez-Lago I
- Subjects
- Adult, Humans, Quality of Life, Retrospective Studies, Treatment Outcome, Crohn Disease drug therapy, Intestinal Fistula etiology, Intestinal Fistula surgery, Rectal Fistula etiology, Rectal Fistula surgery
- Abstract
Background and Aims: Crohn's disease [CD] can develop penetrating complications at any time during the disease course. Enterocutaneous fistulae [ECF] are disease-related complications with an important impact on quality of life. Our aim was to describe the outcomes of this complication, including its medical and/or surgical management and their temporal trends. The primary endpoint was fistula closure, defined as the absence of drainage, with no new abscess or surgery, over the preceding 6 months., Methods: Clinical information from all adult patients with CD and at least one ECF-excluding perianal fistulae-were identified from the prospectively-maintained ENEIDA registry. All additional information regarding treatment for this complication was retrospectively reviewed., Results: A total of 301 ECF in 286 patients [January 1970-September 2020] were analysed out of 30 088 records. These lesions were mostly located in the ileum [67%] and they had a median of one external opening [range 1-10]. After a median follow-up of 146 months (interquartile range [IQR], 69-233), 69% of patients underwent surgery. Fistula closure was achieved in 84%, mostly after surgery, and fistula recurrence was uncommon [13%]. Spontaneous and low-output fistulae were associated with higher closure rates (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.17-1.93, p = 0.001, and HR 1.49, 95% CI 1.07-2.06, p = 0.03, respectively); this was obtained more frequently with medical therapy since biologics have been available., Conclusions: ECF complicating CD are rare but entail a high burden of medical and surgical resources. Closure rates are high, usually after surgery, and fistula recurrence is uncommon. A significant proportion of patients receiving medical therapy can achieve fistula closure., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
27. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
- Author
-
Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, and Domènech E
- Subjects
- Adult, Aged, Chronic Disease, Cohort Studies, Female, Gastrointestinal Agents adverse effects, Humans, Infliximab adverse effects, Middle Aged, Registries, Retrospective Studies, Treatment Outcome, Inflammatory Bowel Diseases chemically induced, Inflammatory Bowel Diseases drug therapy
- Abstract
Background and Aims: Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related adverse events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly patients. We aimed to compare the rates of IFX-related IAEs and loss of response [LOR] in elderly and younger patients., Methods: Adult patients in the ENEIDA registry who had received a first course of IFX therapy were identified and grouped into two cohorts regarding age at the beginning of treatment [over 60 years and between 18 and 50 years]. The rates of IAEs and LOR were compared., Results: In total, 939 patients [12%] who started IFX over 60 years of age and 6844 [88%] below 50 years of age were included. Elderly patients presented a higher proportion of AEs related to IFX [23.2% vs 19%; p = 0.002], infections [7.1% vs 4.3%; p < 0.001] and neoplasms [2.2% vs 0.5%; p < 0.001]. In contrast, the rates of IAEs [14.8% vs 14.8%; p = 0.999], infusion reactions [8.1% vs 8.1%; p = 0.989], late hypersensitivity [1.3% vs 1.2%; p = 0.895], paradoxical psoriasis [1% vs 1.5%; p = 0.187] and drug-induced lupus erythematosus [0.6% vs 0.7%; p = 0.947] were similar in elderly and younger patients. LOR rates were also similar between the two groups [20.5% vs 19.3%; p = 0.438]. In the logistic regression analysis, IFX monotherapy, extraintestinal manifestations and female gender were the only risk factors for IAEs, whereas IFX monotherapy, extraintestinal manifestations and Crohn's disease were risk factors for LOR., Conclusions: Elderly patients with inflammatory bowel disease have a similar risk of developing IFX-related IAEs and LOR to that of younger patients., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
28. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.
- Author
-
Algaba A, Guerra I, Ricart E, Iglesias E, Mañosa M, Gisbert JP, Guardiola J, Mínguez M, Castro B, de Francisco R, Nos P, Bertoletti F, Mesonero F, Barrio J, Martín-Arranz MD, Calvet X, García-López S, Sicilia B, Alcaín G, Esteve M, Márquez L, Piqueras M, Jiménez L, Perez-Calle JL, Bujanda L, García-Sepulcre M, Fernández A, Moraleja I, Lorente RH, García-Bosch O, Lambán A, Blázquez I, Rodríguez E, Huguet JM, Lucendo AJ, Almela P, Busquets D, Ramírez de la Piscina P, Pérez M, Domenech E, and Bermejo F
- Subjects
- Adult, Cross-Sectional Studies, Digestive System Diseases diagnosis, Digestive System Diseases epidemiology, Female, Humans, Joint Diseases diagnosis, Joint Diseases epidemiology, Male, Middle Aged, Prospective Studies, Retrospective Studies, Spain epidemiology, Young Adult, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Registries
- Abstract
Background: Patients with inflammatory bowel disease (IBD) may present extraintestinal manifestations (EIMs) that affect the joints, skin, eyes, and hepatobiliary area, among others., Aims: Our aim was to analyse the prevalence and characteristics of EIMs in patients with IBD and to identify the possible risk factors associated with the development of EIMs in the largest series published to date., Methods: Observational, cross-sectional study including patients from the Spanish ENEIDA registry promoted by GETECCU. We retrospectively identified all cases of EIMs in the ENEIDA registry until January 2018., Results: The study included 31,077 patients, 5779 of whom had at least one EIM (global prevalence 19%; 95% CI 18.2-19.0). Among the different types of EIMs, rheumatic manifestations had a prevalence of 13% (95% CI 12.9-13.7; 63% of EIMs), with a prevalence of 5% (95% CI 4.7-5.2) for mucocutaneous manifestations, 2.1% (95% CI 1.9-2.2) for ocular manifestations, and 0.7% (95% CI 0.6-0.8) for hepatobiliary manifestations. The multivariable analysis showed that the type of IBD (Crohn's disease, p < 0.001), gender (female, p < 0.001), the need for an immunomodulator (p < 0.001) or biologic drugs (p < 0.001), a previous family history of IBD (p < 0.001), and an extensive location of IBD (p < 0.001) were risk factors for the presence of EIMs., Conclusions: One-fifth of patients with IBD may have associated EIMs, with rheumatic manifestations as the most frequent (> 60% of EIMs). Female patients with severe Crohn's disease represent the group with the highest risk of developing EIMs. These patients should therefore be specially monitored and referred to the corresponding specialist when suggestive symptoms appear.
- Published
- 2021
- Full Text
- View/download PDF
29. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
- Author
-
Iborra M, Beltrán B, Fernández-Clotet A, Gutiérrez A, Antolín B, Huguet JM, De Francisco R, Merino O, Carpio D, García-López S, Mesonero F, Navarro P, Ferreiro-Iglesias R, Carbajo AY, Rivero M, Gisbert JP, Piñero-Pérez MC, Monfort D, Bujanda L, García-Sepulcre MF, Martín-Cardona A, Cañete F, Taxonera C, Domènech E, and Nos P
- Subjects
- Adult, Cohort Studies, Crohn Disease epidemiology, Female, Humans, Male, Middle Aged, Registries, Remission Induction methods, Retrospective Studies, Spain epidemiology, Time Factors, Treatment Outcome, Crohn Disease drug therapy, Ustekinumab therapeutic use
- Abstract
Background: There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies., Aim: To assess the real-world, short-term effectiveness of ustekinumab in refractory Crohn's disease (CD) METHODS: Multicentre study of CD patients starting ustekinumab after June 2017 at the recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 mg subcutaneously week 8). Values for Harvey-Bradshaw Index (HBI), C-reactive protein (CRP) and faecal calprotectin (FC) were recorded at baseline and at weeks 8 and 14. Demographic and clinical data, previous treatments, AEs and hospitalisations were documented. Possible predictors of clinical remission were examined., Results: Three hundred and five patients were analysed (≥2 previous anti-TNFα therapies 64% and vedolizumab 29%). At baseline, 217 (72%) had an HBI >4 points. Of these, 101 (47%) and 126 (58%) achieved clinical remission at weeks 8 and 14, respectively. FC levels returned to normal (<250 µg/g) in 46% and 54% of the patients at weeks 8 and 14 respectively. CRP returned to normal (<3 mg/L) in the 35% and 41% of the patients at week 8 and 14 respectively. AEs were recorded in 38, and 40 patients were hospitalised. Intolerance to the most recent anti-TNF agent and fewer previous anti-TNF agents were associated with clinical remission at week 14. Endoscopic severity was associated with poor response., Conclusion: This is the first study to show the real-world effectiveness and safety of ustekinumab administered according to the recommended induction regimen in a cohort of highly refractory CD patients., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
30. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
- Author
-
Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Mañosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Márquez L, Prieto V, García-Sánchez V, Guardiola J, Rodriguez GE, Martín-Arranz MD, García-Tercero I, Sicilia B, Masedo Á, Lorente R, Rivero M, Fernández-Salazar L, Gutiérrez A, Van Domselaar M, López-SanRomán A, Ber Y, García-Sepulcre M, Ramos L, Bermejo F, and Gisbert JP
- Subjects
- Adolescent, Adult, Anti-Inflammatory Agents adverse effects, Case-Control Studies, Cohort Studies, Female, Follow-Up Studies, Gastrointestinal Agents adverse effects, Humans, Incidence, Male, Prognosis, Psoriasis pathology, Spain epidemiology, Withholding Treatment, Adalimumab adverse effects, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Infliximab adverse effects, Psoriasis epidemiology, Psoriasis prevention & control, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Background: Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect., Aim: To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients., Methods: Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes genéticos y Ambientales registry of Grupo Español de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with anti-TNFs without psoriasis were controls. Cox regression analysis was performed to identify predictive factors., Results: Anti-TNF-induced psoriasis was reported in 125 of 7415 patients treated with anti-TNFs (1.7%; 95% CI, 1.4-2). The incidence rate of psoriasis is 0.5% (95% CI, 0.4-0.6) per patient-year. In the multivariate analysis, the female sex (HR 1.9; 95% CI, 1.3-2.9) and being a smoker/former smoker (HR 2.1; 95% CI, 1.4-3.3) were associated with an increased risk of psoriasis. The age at start of anti-TNF therapy, type of inflammatory bowel disease, Montreal Classification, and first anti-TNF drug used were not associated with the risk of psoriasis. Topical steroids were the most frequent treatment (70%), achieving clinical response in 78% of patients. Patients switching to another anti-TNF agent resulted in 60% presenting recurrence of psoriasis. In 45 patients (37%), the anti-TNF therapy had to be definitely withdrawn., Conclusions: The incidence rate of psoriasis induced by anti-TNF therapy is higher in women and in smokers/former smokers. In most patients, skin lesions were controlled with topical steroids. More than half of patients switching to another anti-TNF agent had recurrence of psoriasis. In most patients, the anti-TNF therapy could be maintained.
- Published
- 2016
- Full Text
- View/download PDF
31. Accuracy for optical diagnosis of colorectal polyps in clinical practice.
- Author
-
Sola-Vera J, Cuesta R, Uceda F, Morillo E, Pérez E, Picó MD, Sáez J, Girona E, Buendía L, and García-Sepulcre M
- Subjects
- Adenomatous Polyps diagnostic imaging, Adenomatous Polyps pathology, Adult, Aftercare, Aged, Colonic Neoplasms diagnostic imaging, Colonic Neoplasms pathology, Colonic Polyps pathology, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Sensitivity and Specificity, Colonic Polyps diagnostic imaging, Colonoscopy methods, Narrow Band Imaging
- Abstract
Background: Optical diagnostic involves predicting polyp histopathology from its endoscopic characteristics. It is only recommended for diminutive polyps ( < or = 5 mm) and for predictions made with high confidence., Objectives: To evaluate the accuracy of optical imaging in clinical practice and to assess if optical diagnosis is useful for predicting future colonoscopy surveillance intervals without waiting for histopathological analysis., Methods: consecutive > 18 years patients were enrolled in this prospective study. Colonoscopies were performed by five expert endoscopists who previously participated in an ex-vivo training. Colonoscopes CF-H180AL and CF-Q180AL were used together with Exera II (Olympus Medical System, Tokyo, Japan) processors. Each polyp was characterized in real time using white light and Narrow Band Imaging. Accuracy of optical diagnosis (S, E, NPV, PPV) and correlation between surveillance interval based on optical diagnosis and histopathological analysis were calculated., Results: 311 colon polyps < 10 mm (216 diminutive) in 195 patients were analyzed. Accuracy of optical diagnostics for predictions made with high confidence: Diminutive polyps(sensitivity 0.59, specificity 0.92, NPV 0.48); polyps < 10 mm (sensitivity 0.73, specificity 0.88, NPV 0.50). An optical diagnosis based surveillance recommendation was given to 90 patients. Concordance with histopathology based recommendation was 92.2% according to the European guideline and 93.3% according to the ESGE guideline., Conclusions: Optical diagnostics can be used to predict future surveillance intervals immediately after colonoscopy. However, in this study, based on clinical practice, the accuracy of optical imaging is below the recommended standards.
- Published
- 2015
32. Increased plasma endothelin in liver cirrhosis and response to plasma volume expansion.
- Author
-
García-Sepulcre ME, Carnicer F, Mauri M, Prieto A, and Pérez-Mateo M
- Subjects
- Ascites blood, Case-Control Studies, Humans, Sodium Chloride therapeutic use, Endothelins blood, Liver Cirrhosis blood, Liver Cirrhosis therapy, Plasma Substitutes therapeutic use
- Published
- 1996
33. Esophageal tuberculosis with fistula to mediastinum.
- Author
-
García Sepulcre MF, Casellas Valdé JA, Alonso Maíllo G, Gómez Andrés A, and Carnicer Jáuregui F
- Subjects
- Adult, Esophageal Diseases microbiology, Humans, Male, Esophageal Diseases complications, Esophageal Fistula etiology, Fistula etiology, Mediastinal Diseases etiology, Tuberculosis complications
- Published
- 1995
34. Absence of seasonal variations in peptic ulcer activity and bleeding from peptic ulcer.
- Author
-
García Sepulcre MF, Martinez Sempere JF, Casellas Valdé JA, and Carnicer Jáuregui F
- Subjects
- Female, Humans, Male, Middle Aged, Peptic Ulcer physiopathology, Peptic Ulcer Hemorrhage physiopathology, Spain epidemiology, Peptic Ulcer epidemiology, Peptic Ulcer Hemorrhage epidemiology, Seasons
- Published
- 1995
35. [Neuroendocrine tumor associated with acute pancreatitis].
- Author
-
Martínez Sempere J, Carnicer Jauregui F, Martínez Soler N, García Sepulcre MF, Palazón Azorín JM, and Gómez Andrés A
- Subjects
- Acute Disease, Aged, Female, Humans, Carcinoma, Neuroendocrine complications, Pancreatic Neoplasms complications, Pancreatitis complications
- Abstract
Neuroendocrine pancreatic tumors are uncommon neoplasms. They may remain symptomless for years, and are usually of late diagnosis. A women presenting with severe acute pancreatitis diagnosed as a neuroendocrine tumor after study by the pathologist of the tissue excised at laparotomy is presented.
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.